Diffuse Intrinsic Pontine Glioma - Pipeline Insight, 2025

This “Diffuse Intrinsic Pontine Glioma - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Diffuse Intrinsic Pontine Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Diffuse Intrinsic Pontine Glioma: Understanding

Diffuse Intrinsic Pontine Glioma: Overview

Diffuse intrinsic pontine gliomas (DIPGs) also known as diffuse midline glioma are highly-aggressive and difficult-to-treat brain tumors found at the base of the brain. They are glial tumors, meaning they arise from the brain's glial tissue made up of cells that help support and protect the brain's neurons. These tumors are found in an area of the brainstem called the pons, which controls many of the body's most vital functions such as breathing, blood pressure and heart rate. Approximately 300 children are diagnosed with DIPGs each year, usually between the ages of 5 and 9. Although the prognosis for DIPGs remains very poor but new research, with the help of clinical trials, may provide the key to improved treatment options.

Diffuse Intrinsic Pontine Glioma typically presents with symptoms resulting from brainstem involvement. Common signs include cranial nerve deficits such as facial weakness, difficulty speaking or swallowing, and double vision due to impaired eye movement. Motor symptoms like weakness or coordination issues (ataxia) are frequent, often causing difficulty walking. Other symptoms can include headache, nausea, and vomiting, often linked to increased intracranial pressure.

DIPG is a highly aggressive brain tumor in children, arising in the pons of the brainstem. It is driven by mutations like H3K27M, which disrupt chromatin regulation and alter gene expression, along with mutations in tumor suppressor genes such as TP53 and alterations in pathways like EGFR and TGFBR. These tumors infiltrate surrounding brain tissue, complicating surgery and contributing to poor prognosis. The molecular complexity of DIPG underscores the need for novel therapeutic strategies beyond conventional treatments. Diffuse intrinsic pontine glioma is most commonly diagnosed through imaging studies, as the location of the tumor in the brainstem makes surgical biopsy or removal unsafe. Most diagnoses are based on the tumor’s appearance on MRI scans. When biopsies are performed, the tumors are typically classified as grade III or grade IV, indicating aggressive behavior. These tumors are often identified rapidly due to their fast growth and the sudden onset of symptoms.

The treatment of Diffuse Intrinsic Pontine Glioma a highly aggressive brain tumor primarily affecting children, remains a significant challenge due to the tumor’s infiltrative nature. The standard treatment is radiation therapy, which can provide temporary symptom relief and extend survival by a few months, typically improving the quality of life for about 80% of patients. Emerging treatments under investigation include Proton Beam Radiation, which targets tumors more precisely, and Convection Enhanced Delivery (CED), which allows for direct drug infusion into the tumor, bypassing the blood-brain barrier. Other approaches being explored include immunotherapy and intra-arterial chemotherapy, although these require further clinical trials to establish their efficacy and safety. Despite ongoing research, no curative treatment exists, and the prognosis for DIPG remains poor, with most patients surviving less than a year post-diagnosis.

“Diffuse Intrinsic Pontine Glioma - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Diffuse Intrinsic Pontine Glioma pipeline landscape is provided which includes the disease overview and Diffuse Intrinsic Pontine Glioma treatment guidelines. The assessment part of the report embraces, in depth Diffuse Intrinsic Pontine Glioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diffuse Intrinsic Pontine Glioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diffuse Intrinsic Pontine Glioma R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Intrinsic Pontine Glioma.

Diffuse Intrinsic Pontine Glioma Emerging Drugs Chapters

This segment of the Diffuse Intrinsic Pontine Glioma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, Phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diffuse Intrinsic Pontine Glioma Emerging Drugs

MTX110: Biodexa Pharmaceuticals

MTX110 is a water-soluble formulation of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), and designed for convection-enhanced delivery (CED) to deliver chemotherapeutic doses directly to brain tumors. Panobinostat, a hydroxamic acid and pan-histone deacetylase (HDAC) inhibitor, disrupts tumor growth by altering gene expression through inhibition of deacetylation processes. Unlike the oral formulation of panobinostat lactate (Farydak), which is limited by poor blood-brain barrier penetration, MTX110 bypasses this barrier by being administered directly into or around the tumor via catheter systems, such as CED or fourth ventricle infusions. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of DIPG.

FLAG-003: FLAG Therapeutics

FLAG-003 is a water-soluble, small-molecule therapeutic designed to target and kill cancer cells through two key mechanisms of action: anti-angiogenesis and tubulin inhibition. By binding to three critical cell surface receptors - EGFR, VEGF-R2, and PDGFR-β - FLAG-003 inhibits tumor angiogenesis, cutting off the vascular structure essential for tumor growth. Simultaneously, it disrupts tubulin production, preventing cellular reproduction and inducing tumor cell death. With a remarkably low molecular weight, FLAG-003 can cross the blood-brain barrier (BBB) and evade detection by the Pgp-efflux pump, making it a promising candidate for treating gliomas such as Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma Multiforme (GBM).

Diffuse Intrinsic Pontine Glioma: Therapeutic Assessment

This segment of the report provides insights about the different Diffuse Intrinsic Pontine Glioma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diffuse Intrinsic Pontine Glioma

There are approx. 10+ key companies which are developing the therapies for Diffuse Intrinsic Pontine Glioma. The companies which have their Diffuse Intrinsic Pontine Glioma drug candidates in the most advanced stage, i.e. Phase I/II include Biodexa Pharmaceuticals.

Phases

The report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Diffuse Intrinsic Pontine Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diffuse Intrinsic Pontine Glioma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse Intrinsic Pontine Glioma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse Intrinsic Pontine Glioma drugs.

Diffuse Intrinsic Pontine Glioma Report Insights

• Diffuse Intrinsic Pontine Glioma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diffuse Intrinsic Pontine Glioma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diffuse Intrinsic Pontine Glioma drugs?
• How many Diffuse Intrinsic Pontine Glioma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diffuse Intrinsic Pontine Glioma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diffuse Intrinsic Pontine Glioma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diffuse Intrinsic Pontine Glioma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• FLAG Therapeutics
• Avetabiomics
• Brainchild Bio
• Biodexa Pharmaceuticals
• Kazia Therapeutics

Key Products

• FLAG-003
• AMAX126
• BCB-276
• MTX110
• Paxalisib

This product will be delivered within 2 business days.